Will U.S. Payers Champion Biosimilars?

Value in Health - United Kingdom
doi 10.1016/j.jval.2015.03.1541
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Biosimilars: How Can Payers Get Long-Term Savings?

PharmacoEconomics
Health PolicyPublic HealthOccupational HealthPharmacologyEnvironmental
2016English

Pcn256 - Indication-Specific Pricing in Oncology: How Will U.S. Payers Determine Value Amid This Growing Trend?

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Will Minority Physician Supply Meet U.S. Needs?

Health Affairs
MedicineHealth Policy
1997English

Biosimilars

ESMO Open
Cancer ResearchOncology
2018English

Biosimilars 2.0

mAbs
AllergyImmunology
2011English

Will the U.S. Army Have a Tank in 2020?

1998English

The Death Spiral of Coal in the U.S.: Will Changes in U.S. Policy Turn the Tide?

Climate Policy
Planetary ChangeManagementMonitoringEnvironmental ScienceGlobalAtmospheric SciencePolicyLaw
2019English

Biosimilars in Medicine

Era's journal of medical research
2017English

Champion the Energy Data Revolution

Nature Energy
Energy EngineeringRenewable EnergyFuel TechnologySustainabilityOpticalMagnetic MaterialsPower TechnologyElectronicthe Environment
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy